Shelia D Thomas
Overview
Explore the profile of Shelia D Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muench D, Rezzoug F, Thomas S, Xiao J, Islam A, Miller D, et al.
PLoS One
. 2019 Jan;
14(1):e0211046.
PMID: 30682194
Background: Vascular endothelial growth factor (VEGF) is commonly overexpressed in a variety of tumor types including lung cancer. As a key regulator of angiogenesis, it promotes tumor survival, growth, and...
2.
Sharma V, Thomas S, Miller D, Rezzoug F
Cancer Invest
. 2018 Nov;
36(9-10):475-491.
PMID: 30396283
AS1411 is an antiproliferative DNA aptamer, which binds the ubiquitous protein, nucleolin. In this study, we show that constitutive overexpression of nucleolin confers increased sensitivity to the growth inhibitory effects...
3.
Rezzoug F, Thomas S, Rouchka E, Miller D
PLoS One
. 2016 Aug;
11(8):e0161588.
PMID: 27551915
G-quadruplex forming sequences are particularly enriched in the promoter regions of eukaryotic genes, especially of oncogenes. One of the most well studied G-quadruplex forming sequences is located in the nuclease...
4.
Malik M, OToole M, Casson L, Thomas S, Bardi G, Reyes-Reyes E, et al.
Oncotarget
. 2015 Jun;
6(26):22270-81.
PMID: 26045302
AS1411 is a quadruplex-forming DNA oligonucleotide that functions as an aptamer to target nucleolin, a protein present on the surface of cancer cells. Clinical trials of AS1411 have indicated it...
5.
Chaires J, Trent J, Gray R, Dean W, Buscaglia R, Thomas S, et al.
PLoS One
. 2014 Dec;
9(12):e115580.
PMID: 25526084
Mutations occur at four specific sites in the hTERT promoter in >75% of glioblastomas and melanomas, but the mechanism by which the mutations affect gene expression remains unexplained. We report...
6.
Islam M, Thomas S, Murty V, Sedoris K, Miller D
J Biol Chem
. 2014 Jan;
289(12):8521-31.
PMID: 24464582
Quadruplex-forming DNA sequences are present throughout the eukaryotic genome, including in telomeric DNA. We have shown that the c-Myc promoter quadruplex-forming sequence Pu-27 selectively kills transformed cells (Sedoris, K. C.,...
7.
Miller D, Thomas S, Islam A, Muench D, Sedoris K
Clin Cancer Res
. 2012 Oct;
18(20):5546-53.
PMID: 23071356
The processes of cellular growth regulation and cellular metabolism are closely interrelated. The c-Myc oncogene is a "master regulator" which controls many aspects of both of these processes. The metabolic...
8.
Islam M, Thomas S, Sedoris K, Slone S, Alatassi H, Miller D
Exp Mol Pathol
. 2012 Sep;
94(1):84-90.
PMID: 23000426
The primo vascular system (PVS), which is composed of very small primo-vessels (PV) and primo-nodes (PN), has recently emerged as a third component of circulatory system. Here, we report the...
9.
Sedoris K, Thomas S, Clarkson C, Muench D, Islam A, Singh R, et al.
Mol Cancer Ther
. 2011 Nov;
11(1):66-76.
PMID: 22084162
c-Myc, a key regulator of cell cycle and proliferation, is commonly overexpressed in leukemia and associated with poor prognosis. Conventional antisense oligonucleotides targeting c-myc may attenuate leukemic cell growth, however,...
10.
Sedoris K, Thomas S, Miller D
BMC Cancer
. 2010 Apr;
10:157.
PMID: 20412594
Background: Hypoxic microenvironments in tumors contribute to transformation, which may alter metabolism, growth, and therapeutic responsiveness. The alpha-enolase gene encodes both a glycolytic enzyme (alpha-enolase) and a DNA-binding tumor suppressor...